We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Enoxaparin Versus Unfractionated Heparin in PCI

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00439855
First Posted: February 26, 2007
Last Update Posted: February 26, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Triemli Hospital
  Purpose
Enoxaparin 0.75mg/kg BW is not inferior to weight adjusted unfractionated heparin as anticoagulation for PCI

Condition Intervention Phase
Coronary Artery Disease Drug: Enoxaparin i.v. Drug: unfractionated heparin Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Enoxaparin Versus Unfractionated Heparin in PCI

Resource links provided by NLM:


Further study details as provided by Triemli Hospital:

Primary Outcome Measures:
  • Quadruple endpoint: death, MI, urgent TVR, major bleeding

Secondary Outcome Measures:
  • major bleeding, minor bleeding, thrombocytopenia

Estimated Enrollment: 2100
Study Start Date: September 2003
Estimated Study Completion Date: February 2006
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • PCI for stable ischemia or ACS

Exclusion Criteria:

  • Cardiogenic shock,
  • Pretreatment with study drugs,
  • Lack of informed consent
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00439855


Locations
Switzerland
Division of Cardiology Triemli Hospital Zurich
Zurich, Switzerland, 8063
Sponsors and Collaborators
Triemli Hospital
Investigators
Principal Investigator: osmund bertel, MD Division of Cardiology Triemli Hospital Zurich
  More Information

ClinicalTrials.gov Identifier: NCT00439855     History of Changes
Other Study ID Numbers: ZEUS
First Submitted: February 23, 2007
First Posted: February 26, 2007
Last Update Posted: February 26, 2007
Last Verified: February 2007

Keywords provided by Triemli Hospital:
Enoxaparin, heparin, hemorrhages

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Calcium heparin
Heparin
Anticoagulants
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action